RxDoctor Payments Data

Zachary Beggs, MD

Family Medicine · Rockport, ARNPI 1629634142

Payments from drug & device makers

$742in general payments, 2019–2025

Across 42 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$164
  • GSK$100
  • Novo Nordisk$83
  • AstraZeneca$76
  • Lilly USA, LLC$76
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$38
  • plus $204 from 10 others

What the payments were for

  • Food & beverage$742100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$742 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$124,554
Medicare patients
395
Services billed
2,954

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide51$70,972
JardianceEmpagliflozin34$44,789
RybelsusSemaglutide28$37,640
EliquisApixaban41$32,514
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$24,786
LinzessLinaclotide29$20,209
MounjaroTirzepatide15$15,913
FarxigaDapagliflozin Propanediol17$14,321
UbrelvyUbrogepant12$14,231
QuliptaAtogepant13$13,974
JanuviaSitagliptin Phosphate14$13,016
MyrbetriqMirabegron12$8,991
BrilintaTicagrelor13$8,648
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$8,387
EntrestoSacubitril/Valsartan11$7,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$83$108,61279 claims
AbbVieLinzess, Ubrelvy, Qulipta, Synthroid$164$49,87982 claims
GSKTrelegy Ellipta, Anoro Ellipta$100$33,17350 claims
PfizerEliquis$14$32,51441 claims
AstraZenecaFarxiga, Brilinta$76$22,97030 claims
Lilly USA, LLCMounjaro$76$15,91315 claims
NovartisEntresto$30$7,28311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Rockport

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →